FDA approves J&J’s Tremfya self-injection pen for psoriasis

FDA has approved Johnson & Johnson’s patient-controlled injector for Tremfya, a treatment for adults with moderate to severe plaque psoriasis. The self-injection approval may help Tremfya compete with AbbVie’s (NYSE:ABBV) Humira pen, which was previously approved for self-injection by psoriasis patients. Get the full story on our sister site, Drug Delivery Business.

The post FDA approves J&J’s Tremfya self-injection pen for psoriasis appeared first on MassDevice.